CI Global Health Sciences Corporate Class

Series I CAD

Not available to retail investors / for approved investors only
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date September 2004
CAD Total net assets ($CAD)
As at 2025-05-30
$143.1 million
NAVPS
As at 2025-06-27
$38.2181
MER (%)
As at 2024-09-30
0.00
Management fee (%) Negotiable
Asset class Sector Equity
Currency CAD
Minimum investment Negotiable
Distribution frequency Quarterly
Last distribution $0.6905

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

I 886
A ISC 201
DSC SO* 701
LL SO 1701
E 16005
EF 15005
F 224
O 18005
P 90024
*No new purchases directly into switch only funds.

Performance2 As at 2025-05-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-10.83% -6.92% -17.10% -15.36% -15.43% 2.10% 1.66% 1.96% 8.27%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.6905
2021-03-26 0.2343
2020-12-18 0.3773
2020-09-25 0.3736
2020-06-26 0.2775
Payable date Total
2020-03-20 0.6787
2019-12-13 0.3871
2019-09-27 0.4327
2019-06-21 0.4049
2019-03-22 0.6446

CI PREFERRED PRICING4

Investment amount Combined fee reduction
$100,000 - $500,000 0.03%
$500,000 - $1,000,000 0.06%
$1,000,000 - $2,500,000 0.12%
$2,500,000 - $5,000,000 0.20%
$5,000,000 and above 0.32%

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series I CAD

Not available to retail investors / for approved investors only
 
Portfolio allocations5 As at 2025-05-31
Asset allocation (%)
  • US Equity 83.15
  • International Equity 15.49
  • Cash and Equivalents 1.35
  • Other 0.01
Sector allocation (%)
  • Healthcare 98.56
  • Cash and Cash Equivalent 1.35
  • Other 0.09
Geographic allocation(%)
  • United States 83.92
  • United Kingdom 8.07
  • Switzerland 3.10
  • Germany 2.19
  • Denmark 2.13
  • Canada 0.50
  • Other 0.09
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 10.55%
2. AbbVie Inc Drugs 8.97%
3. Thermo Fisher Scientific Inc Healthcare Equipment 8.35%
4. AstraZeneca PLC Drugs 8.07%
5. Merck & Co Inc Drugs 7.85%
6. UnitedHealth Group Inc Healthcare Services 7.83%
7. DexCom Inc Healthcare Equipment 5.32%
8. Intuitive Surgical Inc Healthcare Equipment 4.74%
9. Stryker Corp Healthcare Equipment 4.57%
10. Gilead Sciences Inc Drugs 4.50%
11. Boston Scientific Corp Healthcare Equipment 4.25%
12. Danaher Corp Healthcare Equipment 4.07%
13. Anthem Inc Healthcare Services 3.98%
14. Lonza Group AG Drugs 3.10%
15. IQVIA Holdings Inc Drugs 3.02%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.